Copaxone in Age Related Macular Degeneration

• Status: Unknown status
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaplan Medical Center
• Treatments: (T,G)-A-L; Glatiramer Acetate

Criteria

Inclusion Criteria:

1. Dry AMD in both eyes

2. Age 50 or above.

3. Signed informed consent.

Exclusion Criteria:

1. Known sensitivity to mannitol or Copaxone.

2. Skin disease or active infection of skin.

3. Active fever or active treatment for infection.

4. History of other active disaese.

5. Premenapausal females not using relibale birth control.

6. Sensitivity for flourescein or iodine.

7. Inability to comply with study procedures.